Drugmakers are expected to increase list prices on more than 1,000 medicines this year, and already raised the prices on ...

Regeneron, maker of the blockbuster ophthalmology medicine Eylea, has acquired an ocular biotech, the large biopharma ...

Hutchmed sells 45% stake in Shanghai venture for $608M, Xgene's pain drug succeeds in Phase 2b, Hookipa buys Poolbeg Pharma, and Capricor gets $10M from Nippon Shinyaku.

Neuroscience drug developer Neumora Therapeutics released highly anticipated results from the first of three Phase 3 trials ...

Nine-figure financings dominated biotech's venture funding landscape, with 96 such rounds tallied by Endpoints News. The bevy of megarounds drowned out smaller ...

Roche pays Innovent Biologics $80M upfront for DLL3-targeting antibody-drug conjugate IBI3009 for small cell lung cancer, ...

Valo Health’s diabetic retinopathy drug failed to improve patients' symptoms in a Phase 2 study, and the company is now on ...

Despite reporting a Phase 3 win this summer, Pfizer terminated its hemophilia A gene therapy pact with Sangamo Therapeutics ...

Ax­some Ther­a­peu­tics on Mon­day re­port­ed da­ta for two Phase 3 stud­ies in Alzheimer’s-re­lat­ed ag­i­ta­tion, say­ing one tri­al suc­ceed­ed while the oth­er … ...

A decade after Bristol Myers Squibb first won approval for its PD-1 checkpoint inhibitor Opdivo, the cancer drug has been ...

BioNTech settles with NIH and UPenn over Comirnaty royalties, paying $750M to NIH and $400M to UPenn for 2020-2023, with ...